At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,703 enrolled
Drug / intervention
MK0974 50 mg +3 moredrug
Likely dose
MK0974 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Oral MK0974 in the Acute Treatment of Migraine With or Without Aura
In Brief
A Phase 3 clinical trial evaluating MK0974 50 mg, MK0974 150 mg, and 2 other interventions for Migraine. Completed, enrolled 1,703 participants.
Detailed Summary
The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2007
Enrollment StartMar 2007
Primary CompletionDec 2007
TodayJul 2026
First PostedFeb 7, 2007
Enrollment StartMar 1, 2007
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 19.4 years ago
Interventions
MK0974 50 mgdrug
MK0974 150 mgdrug
MK0974 300 mgdrug
Comparator: Placebodrug
MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.